ASCO Annual Meeting | Conference

Delaying ADT Until Symptoms Appear Does Not Impact Survival, Study Suggests

May 14th 2014

A rising prostate-specific antigen after surgery or radiation therapy for prostate cancer is not enough reason, on its own, to initiate androgen-deprivation therapy.

AZD9291 Shows Robust Activity in Resistant EGFR-positive NSCLC

May 14th 2014

The highly selective EGFR inhibitor AZD9291 demonstrated an overall response rate of 64% without inducing dose-limiting toxicities in patients with metastatic NSCLC who harbor an acquired EGFR T790M resistance mutation.

Dr. Richard D. Carvajal on the Investigation of Selumetinib

July 25th 2013

Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses the background of the investigation of selumetinib for advanced uveal melanoma.

Dr. Swain Discusses Studies From the 2013 ASCO Meeting

July 15th 2013

Sandra Swain, MD, medical director of the Washington Cancer Institute at MedStar Washington Hospital Center, highlights information presented at the 2013 American Society of Clinical Oncology (ASCO) Meeting.

Dr. Sartor on the Mechanism of Action of Radium-223

July 12th 2013

A. Oliver Sartor, MD, Director of the Tulane Cancer Center, describes the mechanism of action of radium-223 for bone metastases from prostate cancer.

Dr. Gogineni Comments on Oncology Drug Shortages

July 11th 2013

Keerthi Gogineni, MD, MSHP, medical oncologist, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, comments on oncology drug shortages in the U.S.

Dr. Pardee on CPI-613 in Hematologic Malignancies

July 10th 2013

Timothy S. Pardee, MD, describes a phase I trial looking at the first-in-class mitochondrial metabolism inhibitor CPI-613 in patients with advanced hematologic malignancies.

Electra D. Paskett, PhD, on Cervical Cancer Screening

July 9th 2013

Electra D. Paskett, PhD, Professor, College of Medicine, The Ohio State University, discusses the use of vinegar as a cervical cancer screening tool in the U.S.

Dr. Bruce Roth on Curing Cancer With Immunotherapies

July 9th 2013

Bruce Roth, MD, from the Siteman Cancer Center, Washington University School of Medicine, discusses the optimism for a cure with immunotherapies.

Dr. Schuchter Discusses the Treatment of Melanoma

July 3rd 2013

Lynn M. Schuchter, MD, Chief, Hematology Oncology, Department of Medicine, University of Pennsylvania, discusses the treatment of advanced melanoma.

Dr. Gandara on the Heat Shock Protein 90 Inhibitor Ganetespib

July 1st 2013

David R. Gandara, MD, from UC Davis Cancer Center, discusses treatment with the heat shock protein 90 inhibitor ganetespib.

Dr. Mitchell on a Subgroup Analysis of the VELOUR Trial

June 26th 2013

Edith Mitchell, MD, FACP, from Thomas Jefferson University, gives an overview of the North American subgroup analysis of the VELOUR trial.

Dr. Chang on the TRINOVA-1 Trial in Ovarian Cancer

June 25th 2013

David D. Chang, MD, PhD, head of global oncology development at Amgen, discusses the design of the TRINOVA-1 trial in ovarian cancer.

Dr. Robertson on Olaparib for Serous Ovarian Cancer

June 24th 2013

Jane Robertson, MD, Global Product Vice President for olaparib at AstraZeneca, discusses a trial looking at olaparib for patients with serous ovarian cancer.

Dr. Weber Explores Nivolumab in Advanced Melanoma

June 21st 2013

Jeffrey S. Weber, MD, PhD, from the Moffitt Cancer Center and Research Institute, describes a single institution phase I/II trial exploring the anti-PD-1 antibody nivolumab in combination with a peptide vaccine for patients with unresectable melanoma.

Dr. Hudis on the CALGB 40601 Study in Breast Cancer

June 20th 2013

Clifford A. Hudis, MD, chief of the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center in New York, discusses the findings of the CALGB 40601 study in breast cancer.

Dr. Shore on Immunotherapies for Prostate Cancer

June 20th 2013

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, gives an overview of the development of immunotherapies for patients with prostate cancer.

Dr. Wolchok on Concurrent Ipilimumab and Nivolumab

June 19th 2013

Jedd D. Wolchok, MD, PhD, from the Memorial Sloan-Kettering Cancer Center, discusses a phase I trial exploring the combination of the anti-PD-1 antibody nivolumab and ipilimumab, a CTLA-4 inhibitor, for patients with advanced melanoma.

Dr. Goede on the Results from the Phase III CLL11 Trial

June 19th 2013

Valentin Goede, MD, Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany, discusses the findings of the phase III CLL11 trial.

Dr. Lesser on the Background of the RTOG 0424 Study

June 17th 2013

Glenn J. Lesser, MD, discusses the background of the RTOG 0424 study, which analyzed temozolomide in high-risk low-grade gliomas.